LU91140I2 - Duloxètine et ses sels d'addition acides pharmaceutiquement acceptables et particulièrement chlorhydrate de duloxétine (ARICLAIM). - Google Patents

Duloxètine et ses sels d'addition acides pharmaceutiquement acceptables et particulièrement chlorhydrate de duloxétine (ARICLAIM).

Info

Publication number: LU91140I2
Authority: LU; Luxembourg
Prior art keywords: duloxetine; ariclaim; pharmaceutically acceptable; acid addition; addition salts
Prior art date: 1993-11-24

Application number

LU91140C

Other languages

English (en)

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-11-24

Filing date

2005-02-04

Publication date

2005-04-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22566762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91140(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-02-04 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2005-04-04 Publication of LU91140I2 publication Critical patent/LU91140I2/fr

Links

ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 title 1
BFFSMCNJSOPUAY-LMOVPXPDSA-N (S)-duloxetine hydrochloride Chemical compound Cl.C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 BFFSMCNJSOPUAY-LMOVPXPDSA-N 0.000 title 1
239000002253 acid Substances 0.000 title 1
229960002866 duloxetine Drugs 0.000 title 1
229960002496 duloxetine hydrochloride Drugs 0.000 title 1
JFTURWWGPMTABQ-UHFFFAOYSA-N n,n-dimethyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine Chemical compound C=1C=CC2=CC=CC=C2C=1OC(CCN(C)C)C1=CC=CS1 JFTURWWGPMTABQ-UHFFFAOYSA-N 0.000 title 1
150000003839 salts Chemical class 0.000 title 1
206010046543 Urinary incontinence Diseases 0.000 abstract 1
-1 aryloxy propanamines Chemical class 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 abstract 1
229960004688 venlafaxine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Saccharide Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Furan Compounds (AREA)
Pyridine Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
External Artificial Organs (AREA)

LU91140C 1993-11-24 2005-02-04 Duloxètine et ses sels d'addition acides pharmaceutiquement acceptables et particulièrement chlorhydrate de duloxétine (ARICLAIM). LU91140I2 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US15812193A	1993-11-24	1993-11-24

Publications (1)

Publication Number	Publication Date
LU91140I2 true LU91140I2 (fr)	2005-04-04

Family

ID=22566762

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU91140C LU91140I2 (fr)	1993-11-24	2005-02-04	Duloxètine et ses sels d'addition acides pharmaceutiquement acceptables et particulièrement chlorhydrate de duloxétine (ARICLAIM).

Country Status (27)

Country	Link
US (1)	US5744474A (fr)
EP (1)	EP0654264B1 (fr)
JP (1)	JP3681009B2 (fr)
KR (1)	KR100347277B1 (fr)
CN (1)	CN1099284C (fr)
AT (1)	ATE201594T1 (fr)
AU (1)	AU679269B2 (fr)
CA (1)	CA2136120C (fr)
CY (2)	CY2245B1 (fr)
CZ (1)	CZ289069B6 (fr)
DE (2)	DE69427337T2 (fr)
DK (1)	DK0654264T3 (fr)
ES (1)	ES2157958T3 (fr)
GE (1)	GEP20064000B (fr)
GR (1)	GR3036446T3 (fr)
HU (1)	HU218920B (fr)
IL (1)	IL111705A (fr)
LU (1)	LU91140I2 (fr)
NL (1)	NL300174I2 (fr)
NO (2)	NO313535B1 (fr)
PH (1)	PH30741A (fr)
PT (1)	PT654264E (fr)
RU (1)	RU2152786C2 (fr)
SI (1)	SI0654264T1 (fr)
TW (1)	TW344661B (fr)
UA (1)	UA32429C2 (fr)
ZA (1)	ZA949190B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5506270A (en) *	1995-01-30	1996-04-09	American Home Products Corporation	Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
PT888330E (pt) *	1996-03-11	2003-09-30	Lilly Co Eli	Metodos de tratamento ou prevencao de cistite intersticial
PE57198A1 (es) *	1996-03-25	1998-10-10	American Home Prod	Formula de liberacion prolongada
US6274171B1 (en)	1996-03-25	2001-08-14	American Home Products Corporation	Extended release formulation of venlafaxine hydrochloride
EP1331003B1 (fr) *	1996-03-25	2015-08-26	Wyeth LLC	Composition de venlafaxine à libération prolongée
US6150396A (en) *	1997-03-07	2000-11-21	Eli Lilly And Company	Methods of treating or preventing interstitial cystitis
US6579899B1 (en)	1998-07-16	2003-06-17	Massachusetts Institute Of Technology	Composition for treatment of stress
CA2337507A1 (fr) *	1998-07-16	2000-01-27	Massachusetts Institute Of Technology	Composition pour le traitement du stress
DE69942928D1 (de) *	1998-08-27	2010-12-23	Pfizer Health Ab	Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
US6046242A (en) *	1998-11-27	2000-04-04	Basf Aktiengesellschaft	Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6342533B1 (en) *	1998-12-01	2002-01-29	Sepracor, Inc.	Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6197828B1 (en) *	1998-12-01	2001-03-06	Sepracor, Inc.	Derivatives of (+)-venlafaxine and methods of preparing and using the same
PL350924A1 (en) *	1999-04-06	2003-02-10	Sepracor Inc	Derivatives of venlafaxine and methods of preparing and using the same
DE60022692T2 (de) *	1999-07-01	2006-06-22	Pharmacia & Upjohn Co. Llc, Kalamazoo	(S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
US7291646B2 (en)	1999-11-24	2007-11-06	Wyeth	Ethers of O-desmethyl venlafaxine
US6572890B2 (en) *	2000-01-13	2003-06-03	Osmotica Corp.	Osmotic device containing venlafaxine and an anti-psychotic agent
DE10027290C2 (de)	2000-06-02	2002-07-11	Basf Coatings Ag	Pulverklarlackdispersionen (Pulverslurry-Klarlacke) und ihre Verwendung
DE10059412A1 (de) *	2000-11-30	2002-06-13	Gruenenthal Gmbh	Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie der Harninkontinenz
AU2002250058B2 (en) *	2001-02-12	2007-08-16	Wyeth Llc	Novel succinate salt of O-desmethyl-venlafaxine
US6602911B2 (en) *	2001-11-05	2003-08-05	Cypress Bioscience, Inc.	Methods of treating fibromyalgia
IL146462A (en) *	2001-11-13	2015-02-26	Lycored Bio Ltd	Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
CN1630631A (zh) *	2001-12-05	2005-06-22	惠氏公司	新的文拉法星盐酸盐多晶型物及其制备方法
UA77234C2 (en) *	2001-12-05	2006-11-15	Wyeth Corp	Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
GB0202265D0 (en) *	2002-01-31	2002-03-20	Arachnova Therapeutics Ltd	New therapeutic use
AR039164A1 (es) *	2002-03-28	2005-02-09	Synthon Bv	Sales de venlafaxina de baja solubilidad en agua
CN1662231A (zh) *	2002-04-24	2005-08-31	柏树生物科学公司	包括应激相关障碍在内的功能性躯体障碍的预防与治疗
DE10224107A1 (de) *	2002-05-29	2003-12-11	Gruenenthal Gmbh	Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz
AU2003268361A1 (en) *	2002-08-30	2004-03-19	Watson Pharmaceuticals, Inc.	Drug delivery system for treating urinary incontinence
GB0221438D0 (en) *	2002-09-16	2002-10-23	Avecia Ltd	Processes and compounds
EP1424079A1 (fr) *	2002-11-27	2004-06-02	Boehringer Ingelheim International GmbH	Combinaison d'un agoniste du beta-3-récepteur et d'un inhibiteur de recaptage de sérotonine et/ou norépinéphrine
US20070077301A1 (en) *	2002-12-23	2007-04-05	Meyer Glenn A	Venlafaxine osmotic device formulation
JP2006522144A (ja) *	2003-04-04	2006-09-28	ダイノゲンファーマシューティカルズ，インコーポレイテッド	下部尿路障害の治療方法
JP4185154B2 (ja) *	2004-04-30	2008-11-26	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	中枢神経系障害治療用の置換モルホリン化合物
JP5173190B2 (ja)	2004-08-25	2013-03-27	武田薬品工業株式会社	腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
TWI306858B (en) *	2004-12-23	2009-03-01	Teva Pharma	Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
TW200639162A (en) *	2005-03-14	2006-11-16	Teva Pharma	Pure duloxetine hydrochloride
WO2007038253A2 (fr)	2005-09-22	2007-04-05	Teva Pharmaceutical Industries Ltd.	Dnt-maleate, procedes de preparation de dernier
US7994220B2 (en) *	2005-09-28	2011-08-09	Cypress Bioscience, Inc.	Milnacipran for the long-term treatment of fibromyalgia syndrome
PT1954669E (pt)	2005-12-01	2015-10-23	Auspex Pharmaceuticals Inc	Feniletilaminas substituídas com actividade serotoninérgica e/ou norepinefrinérgica
CA2629609A1 (fr)	2005-12-05	2007-06-14	Wyeth	Procede pour la synthese selective d'enantiomeres de 1-(2-amino-1-phenyl-ethyl)-cyclohexanols substitues
EP1863782A1 (fr) *	2005-12-05	2007-12-12	Teva Pharmaceutical Industries Ltd.	2-(n-methyl-propanamine)-3-(2-naphtol)thiophene, une impurete du duloxetine chlorhydrate
EP1826204A1 (fr)	2006-02-28	2007-08-29	Laboratorios Del Dr. Esteve, S.A.	Procédé pour la préparation des précurseurs de duloxetine
US20080081067A1 (en) *	2006-10-03	2008-04-03	Gupta Manishkumar	Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
SI2125698T1 (sl)	2007-03-15	2016-12-30	Auspex Pharmaceuticals, Inc.	Devterirani d9-venlafaksin
JP7485379B2 (ja)	2018-07-11	2024-05-16	ディグニファイセラピューティクスエルエルシー	排泄物貯留を制御するための刺激デバイス

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4314081A (en) *	1974-01-10	1982-02-02	Eli Lilly And Company	Arloxyphenylpropylamines
US4018895A (en) *	1974-01-10	1977-04-19	Eli Lilly And Company	Aryloxyphenylpropylamines in treating depression
PL233786A1 (fr) *	1980-11-14	1982-05-24	Lilly Co Eli
IE56324B1 (en) *	1982-12-13	1991-06-19	American Home Prod	Phenethylamine derivatives and intermediates therefor
US4761501A (en) *	1983-10-26	1988-08-02	American Home Products Corporation	Substituted phenylacetamides
US4956388A (en) *	1986-12-22	1990-09-11	Eli Lilly And Company	3-aryloxy-3-substituted propanamines
KR880007433A (ko) *	1986-12-22	1988-08-27	메리 앤 터커	3-아릴옥시-3-치환된 프로판아민
CA1329937C (fr) *	1987-04-09	1994-05-31	Dennis Charles Thompson	1-phenyl-3-naphtalenyloxpropanamines
US5236956A (en) *	1988-11-04	1993-08-17	Kabi Pharmacia Aktiebolag	Compounds for the treatment of urinary incontinence
SE8804003D0 (sv) *	1988-11-04	1988-11-04	Pharmacia Ab	Compounds for the treatment of urinary incontinence
US5250571A (en) *	1988-11-14	1993-10-05	Eli Lilly And Company	(S)-norfluoxetine in method of inhibiting serotonin uptake
DE3912232A1 (de) *	1989-04-11	1989-11-30	Klosa Josef	Mittel gegen harninkontinenz
CA2061665C (fr) *	1991-02-25	2002-04-16	Mark Mortensen Foreman	Traitement de troubles des voies urinaires inferieures
US5281624A (en) *	1991-09-27	1994-01-25	Eli Lilly And Company	N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
DK0537915T3 (da) *	1991-09-27	1995-11-27	Lilly Co Eli	N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylaminer som inhibitorer for epinephrin
DE69226961T2 (de) *	1991-12-21	1999-04-29	Smithkline Beecham P.L.C., Brentford, Middlesex	Verwendung von 5-ht4 - antagonisten zur herstellung eines arzneimittels zur behandlung von harninkontinenz
US5192751A (en) *	1992-07-24	1993-03-09	Eli Lilly And Company	Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

1994
- 1994-05-12 TW TW083104298A patent/TW344661B/zh not_active IP Right Cessation
- 1994-11-18 CA CA002136120A patent/CA2136120C/fr not_active Expired - Lifetime
- 1994-11-18 ZA ZA949190A patent/ZA949190B/xx unknown
- 1994-11-21 NO NO19944456A patent/NO313535B1/no not_active IP Right Cessation
- 1994-11-21 UA UA94119056A patent/UA32429C2/uk unknown
- 1994-11-21 PH PH49414A patent/PH30741A/en unknown
- 1994-11-21 IL IL11170594A patent/IL111705A/en not_active IP Right Cessation
- 1994-11-22 PT PT94308604T patent/PT654264E/pt unknown
- 1994-11-22 DK DK94308604T patent/DK0654264T3/da active
- 1994-11-22 AT AT94308604T patent/ATE201594T1/de active
- 1994-11-22 JP JP28811994A patent/JP3681009B2/ja not_active Expired - Lifetime
- 1994-11-22 EP EP94308604A patent/EP0654264B1/fr not_active Expired - Lifetime
- 1994-11-22 DE DE69427337T patent/DE69427337T2/de not_active Expired - Lifetime
- 1994-11-22 KR KR1019940030696A patent/KR100347277B1/ko not_active Expired - Lifetime
- 1994-11-22 SI SI9430379T patent/SI0654264T1/xx unknown
- 1994-11-22 DE DE1994627337 patent/DE122005000005I2/de active Active
- 1994-11-22 AU AU78968/94A patent/AU679269B2/en not_active Expired
- 1994-11-22 ES ES94308604T patent/ES2157958T3/es not_active Expired - Lifetime
- 1994-11-23 HU HU9403369A patent/HU218920B/hu unknown
- 1994-11-23 CN CN94118993A patent/CN1099284C/zh not_active Expired - Lifetime
- 1994-11-23 RU RU94041950/14A patent/RU2152786C2/ru active
- 1994-11-23 CZ CZ19942893A patent/CZ289069B6/cs not_active IP Right Cessation
1995
- 1995-04-20 US US08/425,703 patent/US5744474A/en not_active Expired - Lifetime
2001
- 2001-08-27 GR GR20010401296T patent/GR3036446T3/el unknown
- 2001-11-14 CY CY0100037A patent/CY2245B1/xx unknown
2005
- 2005-02-04 LU LU91140C patent/LU91140I2/fr unknown
- 2005-02-09 NO NO2005004C patent/NO2005004I1/no unknown
- 2005-02-10 NL NL300174C patent/NL300174I2/nl unknown
- 2005-02-10 CY CY2005002C patent/CY2005002I1/el unknown
2006
- 2006-05-23 GE GEAP20069411A patent/GEP20064000B/en unknown

Also Published As

Publication number	Publication date
DE69427337D1 (de)	2001-07-05
NO944456D0 (no)	1994-11-21
KR100347277B1 (ko)	2003-03-06
CA2136120C (fr)	2008-01-29
AU679269B2 (en)	1997-06-26
PT654264E (pt)	2001-09-28
EP0654264B1 (fr)	2001-05-30
CN1107699A (zh)	1995-09-06
DK0654264T3 (da)	2001-07-30
DE122005000005I2 (de)	2006-06-08
NO313535B1 (no)	2002-10-21
CY2245B1 (en)	2003-07-04
NL300174I1 (nl)	2005-04-01
TW344661B (en)	1998-11-11
ZA949190B (en)	1996-05-20
IL111705A0 (en)	1995-01-24
IL111705A (en)	2001-01-11
NO944456L (no)	1995-05-26
CZ289069B6 (cs)	2001-10-17
NL300174I2 (nl)	2005-05-02
RU94041950A (ru)	1996-09-20
DE122005000005I1 (de)	2005-05-12
CY2005002I2 (el)	2010-07-28
HUT72317A (en)	1996-04-29
ATE201594T1 (de)	2001-06-15
UA32429C2 (uk)	2000-12-15
RU2152786C2 (ru)	2000-07-20
NO2005004I1 (no)	2005-02-10
US5744474A (en)	1998-04-28
JP3681009B2 (ja)	2005-08-10
GR3036446T3 (en)	2001-11-30
AU7896894A (en)	1995-06-01
CY2005002I1 (el)	2010-07-28
SI0654264T1 (en)	2001-10-31
JPH07188003A (ja)	1995-07-25
KR950013511A (ko)	1995-06-15
HU218920B (hu)	2000-12-28
DE69427337T2 (de)	2001-10-31
EP0654264A1 (fr)	1995-05-24
HU9403369D0 (en)	1995-02-28
GEP20064000B (en)	2006-12-11
ES2157958T3 (es)	2001-09-01
HK1013799A1 (en)	1999-09-10
PH30741A (en)	1997-10-17
CN1099284C (zh)	2003-01-22
CA2136120A1 (fr)	1995-05-25
CZ289394A3 (en)	1995-07-12

Publication	Publication Date	Title
LU91140I2 (fr)	2005-04-04	Duloxètine et ses sels d'addition acides pharmaceutiquement acceptables et particulièrement chlorhydrate de duloxétine (ARICLAIM).
TW262468B (fr)	1995-11-11
EP0659416A3 (fr)	1995-09-06	Inhibition de séborrhée et de l'acné.
MY132056A (en)	2007-09-28	Methods of inhibiting physiological conditions associated with an excess of neuropeptide y.
DE69402173D1 (de)	1997-04-24	Hemmung von Thrombin
ZA944739B (en)	1995-10-10	Amide and urea derivatives having anti-hypercholesteremic activity their preparation and their therapeutic uses
NO943878L (no)	1995-04-18	Hemming av uterinfibrose
NO943875D0 (no)	1994-10-13	Hemming av angiogenese og angiogene sykdommer
MX9709475A (es)	1998-02-28	Derivados de pirrol y composicion medicinal.
NO943873D0 (no)	1994-10-13	Hemming av bruskdegradering
AU7578694A (en)	1995-05-04	Methods for treating resistant neoplasms
ES2157961T3 (es)	2001-09-01	Inhibicion del hirsutismo y la alopecia en mujeres.
CA2561293A1 (fr)	1995-05-25	Traitement de l'incontinence